Neurological biomarkers are criteria used to evaluate and measure the response of pharmacological treatment for specific diseases such as Parkinson's disease, autism, and depression. They play a crucial role in disease identification. The main types of neurological biomarkers include imaging, genomics, proteomics, and metabolomics. These biomarkers provide valuable insights into the understanding and diagnosis of neurological disorders, aiding in the development of targeted treatments and interventions.
According to Data Bridge Market Research, the Neurological Biomarkers Market accounted for USD 6.92 billion in 2022, and expected to reach USD 21.45 billion by 2030. The market is expected to grow with a CAGR of 13.4% in the forecast period of 2023 to 2030.
“Increasing technological advancements by market players”
Recent breakthroughs in biomarkers, including biomarker signatures, have improved the treatment prospects for neurological diseases. This has led to accelerated drug development, non-invasive testing methods, and early disease detection. In order to support biomarker-related research such as discovery, analytical validation, and clinical validation, the National Institute of Neurological Disorders and Stroke offers funding opportunities like development grants and cooperative agreements. This factor significantly contributes to the growth of the market.
What restraints the growth of the neurological biomarkers market?
“Lack of performance of neurological biomarkers”
The performance of biomarkers in detecting illnesses can vary, leading to a time-consuming assessment process. As a result, the validation process becomes expensive and time-intensive. The development and validation timelines for biomarkers are generally similar across different categories, with some exceptions, as various biomarker types often share common phases in their development and validation. This factor hinders the growth of the market due to the challenges and resources required in the process of developing and validating biomarkers.
Segmentation: Global Neurological Biomarkers Market
The neurological biomarkers market is segmented on the basis of product type, indication, imaging techniques, services, and end user.
- On the basis of product type, the neurological biomarkers market is segmented into genomics biomarker, proteomics biomarker, imaging biomarker, metabolomics biomarker, others.
- On the basis of indication, the neurological biomarkers market is segmented into spinal muscular atrophy, parkinson's disease, schizophrenia, huntington's disease, alzheimer's disease, depression, multiple sclerosis.
- On the basis of imaging techniques, the neurological biomarkers market is segmented into transcranial magnetic stimulation, diffusion tensor imaging, conventional structural mri, functional magnetic resonance imaging, positron emission tomography.
- On the basis of services, the neurological biomarkers market is segmented into sample preparation, assay development, biomarker validation and testing.
- On the basis of end user, the neurological biomarkers market is segmented into clinical diagnostics, pharmaceutical and biotechnology companies, research organizations.
Regional Insights: North America dominates the Neurological Biomarkers Market
North America dominates the market because of the increase in healthcare expenditure and huge commercial performances of neurological diagnostics in the U.S. Furthermore, the growing product launches combined with the increase in demand for biomarkers are anticipated to impact the regional market positively.
Asia-Pacific is expected to be the fastest developing region during the forecast period of 2023-2030 because of the region's improvement in healthcare infrastructure and increase in disposable income. Also, an increasing number of clinical trials being performed in emerging countries, such as India and China, leads to market growth.
To know more about the study visit, https://www.databridgemarketresearch.com/fr/reports/global-neurological-biomarkers-market
Recent Developments in Neurological Biomarkers Market
- In 2020, Johnson & Johnson Services, Inc. entered into a strategic agreement with Enigma Biomedical Group to assess novel neuroimaging biomarkers-JNJ-64413739 and JNJ-64511070-to understand Alzheimer's disease and other dementias.
The Prominent Key Players Operating in the Neurological Biomarkers Market Include:
- Thermo Fisher Scientific (U.S.)
- QIAGEN (Netherlands)
- Agilent Technologies, Inc. (U.S.)
- McKesson Corporation (U.S)
- R1 RCM Inc., (U.S)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Bio-Rad Laboratories, Inc. (U.S.)
- BGI (China), Quanterix (U.S.)
- bioMérieux Inc (U.S.)
- Neurosteer Inc. (U.S.)
- Advanced Brain Monitoring, Inc (U.S.)
Above are the key players covered in the report, to know about more and exhaustive list of neurological biomarkers market companies contact, https://www.databridgemarketresearch.com/fr/contact
Research Methodology: Global Neurological Biomarkers Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
